Navigation Links
Icahn Confirms Intention to Nominate Three Directors at Biogen
Date:1/28/2008

reholders should share his concern that Biogen may attempt to make an acquisition for the purpose of making it unattractive to, or reducing the number of, future potential buyers. In fact, Mr. Icahn noted that The Times of London reported on Saturday that Biogen may be considering a bid for a European biotech company. Mr. Icahn stressed that he reserved the right to oppose any "toxic" transactions by all available means.

The slate of directors to be nominated by Mr. Icahn and his affiliates consists of Alexander J. Denner whose principal occupation is Managing Director of entities controlled by Mr. Icahn that manage private investment funds, Professor Anne B. Young, who is Julianne Dorn Professor of Neurology at Harvard Medical School and Chief, Neurology Service at Massachusetts General Hospital, and Professor Richard C. Mulligan, who is Mallinckrodt Professor of Genetics at Harvard Medical School, and Director of the Harvard Gene Therapy Initiative.

"We determined to run a slate of three directors to ensure that if the slate were to be elected and Biogen's management failed to act to enhance shareholder value, shareholders would have the opportunity to elect sufficient new directors in 2009 who, together with our slate of 2008 directors, would constitute a majority of the board."

SECURITY HOLDERS ARE ADVISED TO READ THE PROXY STATEMENT AND OTHER DOCUMENTS RELATED TO SOLICITATION OF PROXIES BY MR. ICAHN AND HIS AFFILIATES FROM THE STOCKHOLDERS OF BIOGEN IDEC INC. WHEN AND IF THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. THEY ARE OR WILL BE AVAILABLE WITHOUT CHARGE ON THE SECURITIES AND EXCHANGE COMMISSIONS'S WEBSITE AT HTTP://WWW.SEC.GOV. WHEN AND IF COMPLETED, A DEFINITIVE PROXY STATEMENT AND A FORM OF PROXY WILL BE MAILED AND/OR MADE ELECTRONICALLY AVAILABLE TO STOCKHOLDERS OF BIOGEN IDEC INC. AND WILL ALSO BE AVAILABLE AT NO CHARGE AT '/>"/>

SOURCE Icahn
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Barr Confirms Patent Challenge of Namenda(R) Tablets, 5mg & 10mg
2. Barr Confirms Patent Challenge of Eloxatin(R) Injectable, 5mg/mL
3. Barr Confirms Patent Challenge of Focalin(R) XR
4. Recent Study Confirms Alimentary Healths Bifantis(R) Demonstrates Efficacy in the Treatment of Irritable Bowel Syndrome
5. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
6. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
7. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
8. BioMS Medical announces its intention to renew a normal course issuer bid
9. Emmy(R)- and Golden Globe(R)-Nominated Actress Marcia Cross to Join Lifetime Networks and Members of Congress From Both Parties at Capitol Hill Press Conference
10. Roche to Nominate Independent Directors for Election at Ventanas 2008 Annual Stockholders Meeting
11. SDCRM Receives Highest Score in Three of Four Categories from CIRM on Part I of Major Facilities Grant Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014  Replikins Ltd. today released ... the Ebola virus. Before the current outbreaks, the mean ... 100 amino acids) between 1995 and 2002 was 1.1; ... in 2012, and sixteen-fold in 2013, thus predicting the ... this technology has been shown to be able to ...
(Date:7/30/2014)... Albany, NewYork (PRWEB) July 30, 2014 ... population, the increase of personal health expenditure as ... government health care system, China diagnostic reagent industry ... reagents occupy over 90%. In 2013, Chinese in ... which RMB16.61 billion came from in vitro diagnostic ...
(Date:7/30/2014)...  Orexigen Therapeutics, Inc. (Nasdaq: OREX ) ... of Outstanding Issues (LOI) from the European Medicines Agency,s ... the NB32 Marketing Authorization Application (MAA). NB32 (naltrexone sustained ... candidate being evaluated for weight loss. The ... were adequately addressed by the Company based in part ...
(Date:7/30/2014)... July 30, 2014  RXi Pharmaceuticals Corporation ... company focused on discovering, developing and commercializing ... using RNA-targeted technologies, today announced that their ... for the reduction of recurrence of hypertrophic ... been initiated. Logo - ...
Breaking Biology Technology:China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5
... GREENWOOD VILLAGE, Colo., Dec. 22, 2011 Ampio Pharmaceuticals, ... or the "Company"), a company that discovers and develops ... entities ("NMEs"), today announced notification of the granting of ... METHOD OF USING DIKETOPIPERAZINES AND COMPOSITION CONTAINING THEM". ...
... Mich., Dec. 22, 2011  Neogen Corporation (NASDAQ: NEOG ... of FY 2012, which ended Nov. 30, increased 2.2% from ... the quarter was $5,237,000, or $0.22 per share, compared to ... $0.26 per share. Year-to-date revenues for the first ...
... 2011 Epitomics, Inc., a California based biotech ... a Star Program in collaboration with the University ... application of a new, advanced antibody assay technique, ... measurements of antibody-antigen interactions. Over the course of ...
Cached Biology Technology:Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™ 2Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™ 3Neogen Reports Second Quarter Results 2Neogen Reports Second Quarter Results 3Neogen Reports Second Quarter Results 4Neogen Reports Second Quarter Results 5Neogen Reports Second Quarter Results 6Epitomics, Inc. and University of California, Davis, Complete Star Program for High-Throughput Measurement of Antibody-Antigen Interactions 2
(Date:7/30/2014)... pieces is still in its infant stage. But it ... major significance. "Amazingly often, we are findingin addition to ... we found in Baltic amber," explained Bonn paleontologist Professor ... from the Baltic Sea region, which is almost 10,000 ... the coastal regions of Mecklenburg, Poland and Belarus. The ...
(Date:7/30/2014)... unveiled the first high-resolution map of the carbon ... of Per. The new and improved methodology used ... for future market-based carbon economies. The new ... diversity and it provides the critical input to ... land use, and enforcement purposes. The technique includes ...
(Date:7/29/2014)... Bristol,s Nutrition and Behaviour Unit (NBU) has looked into ... meals. , The research, to be presented at the ... 2014) in Seattle, USA this week [29 July to ... was led by Professor Jeff Brunstrom, and is based ... of a Biotechnology and Biological Sciences Research Council (BBSRC) ...
Breaking Biology News(10 mins):Chinese mosquitos on the Baltic Sea 2Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3
... Los Angeles, London, New Delhi, Singapore and Washington DC (July ... be advertised directly to the patient, and the results of ... the future adoption of pharmacogenetic/genomic testing, according to a position ... be published in the August 2009 issue of the ...
... many couples conceive healthy children and is generally considered ... PGD in mice suggests that this procedure may increase ... PGD is used alongside assisted reproduction technologies ... disease (e.g. Ashkenazi Jews who have a high incidence ...
... the July issue of Biomaterials , published by ... report on the first lab-grown motor nerves that are ... human body. The model system will drastically improve ... diabetic neuropathy and later, possibly multiple sclerosis (MS). In ...
Cached Biology News:Genetic tests advertised directly to the consumer 2Preimplantation genetic diagnosis may pose neurological risks 2Researchers design first model motor nerve system that's insulated and organized like the human body 2
Applications: Western blotting ...
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
Required to perform reference file generation, flatfield calibration and performance verification processes on the GSD-501...
... Amplification Kit, 100 reactions. Prepare circular ... 4-6 h.Generate microgram quantities of template ... material.Use amplified DNA directly for cycle ... or M13 liquid cultures, colonies, plaques, ...
Biology Products: